Novartis tests pill to calm heart disease inflammation
NCT ID NCT06031844
Summary
This study tested whether a new daily pill called DFV890 could safely reduce specific markers of inflammation in the blood of people with coronary heart disease. About 24 adults who had a prior heart attack and high inflammation levels took either the drug or a placebo for 12 weeks. The main goal was to see how well the drug lowered inflammation markers like IL-6 and IL-18, which are linked to heart disease risk.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY HEART DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Excel Medical Clinical Trials LLC
Boca Raton, Florida, 33434, United States
-
Monument Health Clinical Research
Rapid City, South Dakota, 57701, United States
-
Novartis Investigative Site
Montreal, Quebec, H1T 1C8, Canada
-
Triad Clinical Trials LLC
Greensboro, North Carolina, 27410, United States
-
UF Health Science Center
Jacksonville, Florida, 32209, United States
-
Universal Research Group LLC
Tacoma, Washington, 98405, United States
-
Valley Clinical Trials
Northridge, California, 91325, United States
Conditions
Explore the condition pages connected to this study.